1. Search Result
Search Result
Results for "

( )-Lithospermic acid

" in MedChemExpress (MCE) Product Catalog:

3335

Inhibitors & Agonists

73

Fluorescent Dye

290

Biochemical Assay Reagents

1646

Peptides

520

Natural
Products

3

Recombinant Proteins

42

Isotope-Labeled Compounds

81

Click Chemistry

42

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0823
    Lithospermic acid
    4 Publications Verification

    (+)-Lithospermic acid

    NO Synthase AMPK Keap1-Nrf2 Xanthine Oxidase Apoptosis Cardiovascular Disease Inflammation/Immunology
    Lithospermic acid ((+)-Lithospermic acid) is a plant-derived polycyclic phenolic carboxylic acid isolated from Salvia miltiorrhiza, and has the anti-oxidative and hepatoprotective activity on carbon tetrachloride (CCl4)-induced acute liver damage in vitro and in vivo .
    Lithospermic acid
  • HY-N1362
    Salvianolic acid B
    15+ Cited Publications

    Lithospermic acid B

    Autophagy Cardiovascular Disease
    Salvianolic acid B is an active ingredient of Salvia miltiorrhiza, which has been widely applied in China for the management of various microcirculation-related disorders, such as cardiovascular disease, cerebrovascular disease, and diabetic vascular complication.
    Salvianolic acid B
  • HY-P0041A

    Vasopressin Receptor Neurological Disease
    F992 TFA is an antidiuretic peptide and vasopressin (antidiuretic hormone) analogue .
    F992 TFA
  • HY-P10218A

    MARCKS PKC Inflammation/Immunology Cancer
    MANS peptide TFA is the TFA salt form of MANS peptide (HY-P10218). MANS peptide TFA is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .
    MANS peptide TFA
  • HY-P10218

    MARCKS PKC Inflammation/Immunology Cancer
    MANS peptide is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .
    MANS peptide
  • HY-N0823R

    (+)-Lithospermic acid (Standard)

    Reference Standards NO Synthase AMPK Keap1-Nrf2 Xanthine Oxidase Apoptosis Cardiovascular Disease Inflammation/Immunology
    Lithospermic acid (Standard) is the analytical standard of Lithospermic acid. This product is intended for research and analytical applications. Lithospermic acid ((+)-Lithospermic acid) is a plant-derived polycyclic phenolic carboxylic acid isolated from Salvia miltiorrhiza, and has the anti-oxidative and hepatoprotective activity on carbon tetrachloride (CCl4)-induced acute liver damage in vitro and in vivo .
    Lithospermic acid (Standard)
  • HY-N8931

    Lithospermic acid monomethyl ester

    Akt Neurological Disease
    Monomethyl lithospermate activates the PI3K/AKT pathway, which plays a protective role in nerve injury. Monomethyl lithospermate can improve the survival ability of SHSY-5Y cells, inhibit the breakdown of mitochondrial membrane potential (MMOP) and inhibit cell apoptosis. Monomethyl lithospermate also reduced the level of oxidative stress in the brain tissue of rats with middle artery occlusion (MCAO) and improved nerve damage in rats with ischemic stroke (IS) .
    Monomethyl lithospermate
  • HY-N1362R

    Lithospermic acid B (Standard)

    Reference Standards Autophagy Cardiovascular Disease
    Salvianolic acid B (Standard) is the analytical standard of Salvianolic acid B. This product is intended for research and analytical applications. Salvianolic acid B is an active ingredient of Salvia miltiorrhiza, which has been widely applied in China for the management of various microcirculation-related disorders, such as cardiovascular disease, cerebrovascular disease, and diabetic vascular complication.
    Salvianolic acid B (Standard)
  • HY-P10876

    Amyloid-β Neurological Disease
    mcK6A1 is an inhibitor for the aggregation of amyloid-β (), that selectively binds to the 16KLVFFA21 segment of Aβ42, forms an extended β-folded structure, and inhibits the formation of Aβ42 oligomers. mcK6A1 can be used in research of Alzheimer's disease and other amyloid-related diseases .
    mcK6A1
  • HY-P0041

    Vasopressin Receptor Neurological Disease
    F992 is an antidiuretic peptide and vasopressin (antidiuretic hormone) analogue .
    F992
  • HY-169089A

    Drug Derivative Cancer
    RP-182-PEG3-K(palmitic acid) (Compound 1a) TFA is a fatty acid derivative of the immunomodulatory peptide RP-182. RP-182-PEG3-K(palmitic acid) TFA inhibits CD206 high M2-like macrophage (IC50 of 3.2 μM) and induces phagocytosis. RP-182-PEG3-K(palmitic acid) TFA exhibits antitumor efficacy in mouse B16 melanoma allografts .
    RP-182-PEG3-K(palmitic acid) TFA
  • HY-169089

    Drug Derivative Cancer
    RP-182-PEG3-K palmitic acid (Compound 1a) is a fatty acid derivative of the immunomodulatory peptide RP-182. RP-182-PEG3-K palmitic acid inhibits CD206 high M2-like macrophage (IC50 of 3.2 μM) and induces phagocytosis. RP-182-PEG3-K palmitic acid exhibits antitumor efficacy in mouse B16 melanoma allografts .
    RP-182-PEG3-K(palmitic acid)
  • HY-P2231
    Cotadutide
    1 Publications Verification

    MEDI0382

    GCGR Metabolic Disease
    Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D) .
    Cotadutide
  • HY-P2231A
    Cotadutide acetate
    1 Publications Verification

    MEDI0382 acetate

    GCGR Metabolic Disease
    Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D) .
    Cotadutide acetate
  • HY-P0014A

    GLP Receptor Metabolic Disease
    Liraglutide acetate is the acetate form of Liraglutide (HY-P0014), a glucagon-like peptide-1 (GLP-1) receptor agonist studied in type 2 diabetes .
    Liraglutide acetate
  • HY-P0014
    Liraglutide
    25+ Cited Publications

    GCGR GLP Receptor Metabolic Disease Cancer
    Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.
    Liraglutide
  • HY-P10869
    dCNP
    1 Publications Verification

    Natriuretic Peptide Receptor (NPR) Inflammation/Immunology Cancer
    dCNP binds to NPR-B/C receptor, activates cGMP signaling pathway, and regulates vascular function. dCNP exhibits anti-hypoxia property through downregulation of hypoxia-related genes expressions like HIF1α and HIF2α. dCNP inhibits the induction of tumor stroma and exhibits anti-fibrosis activity. dCNP upregulates CTLs, NK cells, and conventional type 1 dendritic cells in tumors, and activates immune responses .
    dCNP
  • HY-P0014B
    Liraglutide TFA
    25+ Cited Publications

    GLP Receptor Metabolic Disease
    Liraglutide (TFA) is an agonist of glucagon-like peptide 1 receptor (GLP-1). Liraglutide (TFA) can activate GLP-1, leading to the release of insulin in the presence of increased glucose concentration. Liraglutide (TFA) also reduces glucagon secretion in a glucose-dependent manner. Liraglutide (TFA) can be studied in research on type 2 diabetes .
    Liraglutide TFA
  • HY-P10318

    GLP Receptor Endocrinology
    SHR-2042 is a selective agonist of the GLP-1 receptor.SHR-2042 improves glycemic control by activating the GLP-1 receptor, enhancing insulin secretion and inhibiting glucagon secretion. SHR-2042 combined with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) promotes monomerization through the formation of micelles and improves oral absorption efficiency .
    SHR-2042
  • HY-P10200

    Bacterial Infection
    CP7-FP13-2 is a peptide with antivirulence factor and antibacterial activity. CP7-FP13-2 inhibits the formation of Staphylococcus aureus biofilm and has good antibacterial efficacy in mice .
    CP7-FP13-2
  • HY-P3291
    Dapiglutide
    1 Publications Verification

    ZP7570

    GCGR Metabolic Disease
    Dapiglutide (ZP7570) is a long-acting glucagon-like peptide-1 receptor 1R (GLP-1R)/Glucagon-like peptide-2 receptor (GLP-2R) dual agonist. Dapiglutide alleviates intestinal dysfunction in a mouse short bowel model and has anti-obesity effects .
    Dapiglutide
  • HY-P11233

    GLP Receptor Metabolic Disease
    Acmopatide (Compound E-153) is a dual-acting GIP/GLP-1 receptor agonist. Acmopatide is used in anti-diabetic research .
    Acmopatide
  • HY-P5161

    GLP Receptor GCGR Metabolic Disease
    FC382K10W15 is a glucagon analogue and GLP-1R/GCGR agonist. FC382K10W15 can be used in type 2 diabetes research .
    FC382K10W15
  • HY-P5161A

    GLP Receptor GCGR Metabolic Disease
    FC382K10W15 TFA is a glucagon analogue and GLP-1R/GCGR agonist. FC382K10W15 TFA can be used in type 2 diabetes research .
    FC382K10W15 TFA
  • HY-P3462
    Cagrilintide
    3 Publications Verification

    CGRP Receptor Metabolic Disease
    Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity .
    Cagrilintide
  • HY-P3462A
    Cagrilintide acetate
    3 Publications Verification

    CGRP Receptor Metabolic Disease
    Cagrilintide acetate is a non-selective AMYR/CTR agonist and long-acting acylated amylase analogue. Cagrilintide acetate causes a reduction in food intake and significant weight loss in a dose-dependent manner. Cagrilintide acetate can be used in obesity studies .
    Cagrilintide acetate
  • HY-P3143

    PD-1/PD-L1 Cancer
    BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC50 of 7.68 nM. BMSpep-57 binds to PD-L1 with Kds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 facilitates T cell function by in creasing IL-2 production in PBMCs .
    BMSpep-57
  • HY-P3143A

    PD-1/PD-L1 Cancer
    BMSpep-57 hydrochloride is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC50 of 7.68 nM. BMSpep-57 hydrochloride binds to PD-L1 with Kds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 hydrochloride facilitates T cell function by in creasing IL-2 production in PBMCs .
    BMSpep-57 hydrochloride
  • HY-P0014AS

    Isotope-Labeled Compounds GLP Receptor Metabolic Disease
    Liraglutide-d8 tetraTFA is deuterium labeled Liraglutide (HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .
    Liraglutide-d8 tetraTFA
  • HY-P0014S2

    Isotope-Labeled Compounds Others
    Liraglutide- 13C6, 15N (TFA)is the 13C and 15N labeledLiraglutide(HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus .
    Liraglutide-13C6,15N TFA
  • HY-P0014S1

    Isotope-Labeled Compounds GLP Receptor GCGR Others
    Liraglutide- 13C5, 15N (tetraTFA) is the 13C and 15N labeled Liraglutide (HY-P0014) . Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus .
    Liraglutide-13C5,15N TFA
  • HY-P10271

    NNC0090-2746; MAR709; RO6811135

    GLP Receptor Metabolic Disease
    RG7697 is a dual agonist for glucagon-like peptide receptor (GLP Receptor) and glucosedependent insulinotropic polypeptide receptor (GIPR), with EC50 of 5 and 3 pM, respectively. RG7697 exhibits antihyperglycemic property .
    RG7697
  • HY-P10341

    GCGR Metabolic Disease
    ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .
    ZP3022
  • HY-113560

    Antibiotic Fungal Phospholipase Infection
    Plipastatin B1 is a lipopeptide antibiotic, an inhibitor of phospholipase A2 (PLA2), which has antifungal activity .
    Plipastatin B1
  • HY-P11273

    OK 101

    Biochemical Assay Reagents Inflammation/Immunology
    Urcosimod (OK 101) is an immunomodulator and anti-inflammatory agent .
    Urcosimod
  • HY-P11290

    Melanocortin Receptor Metabolic Disease
    MC4-NN2-0453, a α-MSH analog, is a selective MC4R agonist. MC4-NN2-0453 can be used for obesity research .
    MC4-NN2-0453
  • HY-P1162

    SKF 100273

    Vasopressin Receptor Metabolic Disease
    (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin (SKF 100273) is a vasopressin V1 receptor selective antagonist .
    (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin
  • HY-P2595

    Endogenous Metabolite Cardiovascular Disease
    SKF 103784 is an vasopressin antagonist with activity against vasopressin. SKF 103784 inhibits the physiological response caused by antidiuretic and is therefore used to study biological processes related to water and salt balance. SKF 103784 can also be used to explore pathological mechanisms related to cardiovascular diseases and endocrine dysfunction .
    SKF 103784
  • HY-153476

    GCGR Metabolic Disease
    GIP/GLP-1 dual receptor agonist-1 (compound 4) is a GIP/GLP-1 receptor agonist. GIP/GLP-1 dual receptor agonist-1 can be used in the research of metabolic disorders and fatty liver diseases, including nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD) .
    GIP/GLP-1 dual receptor agonist-1
  • HY-153476A

    Insulin Receptor GLP Receptor Metabolic Disease
    GIP/GLP-1 dual receptor agonist-1 (Compound 4) (sodium) is a GIP/GLP-1 receptor agonist. GIP/GLP-1 dual receptor agonist-1 (sodium) can be used in the research of metabolic disorders and fatty liver diseases, including nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD).
    GIP/GLP-1 dual receptor agonist-1 sodium
  • HY-P4895

    Oxytocin Receptor Neurological Disease
    (d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin (OVT) is an oxytocin receptor antagonist. (d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin can be used for the research of neurological disease .
    (d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin
  • HY-P10272

    PTG-300

    Ferroportin Others
    Rusfertide is a peptide mimetic of natural hepcidin, which targets and degrades ferroportin, reduces serum iron and transferrin-saturation, and thus regulates the production of red blood cells. Rusfertide ameliorates the polycythemia vera, β-thalassemia and hereditary hemochromatosis .
    Rusfertide
  • HY-P10881

    Peptide-Drug Conjugates (PDCs) Metabolic Disease
    Ganipatide is a 1-31-Glucose-dependent insulinotropic polypeptide. Ganipatide is promising for research of diabetes .
    Ganipatide
  • HY-157084

    ROS Kinase Bacterial Infection
    HS-291 is a HtpG inhibitor of Borrelia burgdorferi (Bb). HS-291 contains BX-2819 (high affinity for Bb HtpG), PEG linker, and Verteporfin (HY-B0146) (a photoactive toxin).HS-291 produces reactive oxygen species under light activation to oxidize HtpG and a discrete protein subset near chaperone proteins and can quickly and irreversibly inactivate Bb .
    HS-291
  • HY-P10563

    BHV-1100

    CD38 Cancer
    Noraramtide (BHV-1100) is an antibody recruitment molecule. Noraramtide can specifically bind to CD38 molecules to recruit natural killer (NK) cells. Noraramtide enhances the ability of NK cells to kill tumor cells through antibody-dependent cellular cytotoxicity (ADCC). This mechanism allows NK cells to more effectively recognize and eliminate tumor cells while avoiding mutual killing between NK cells. Noraramtide can be used for the study of autologous cancer immunity .
    Noraramtide
  • HY-P5524A

    Lauroyl-γ-D-glutamyl-meso-diaminopimelic acid hydrochloride; γ-D-glutamyl-meso-diaminopimelic acid hydrochloride

    NOD-like Receptor (NLR) Others
    C12-iE-DAP hydrochloride is the hydrochloride salt form of C12-iE-DAP (HY-P5524). C12-iE-DAP hydrochloride is a biologically active peptide that has agonistic effects on NOD1 .
    C12-iE-DAP hydrochloride
  • HY-P5524

    Lauroyl-γ-D-glutamyl-meso-diaminopimelic acid; γ-D-glutamyl-meso-diaminopimelic acid

    NOD-like Receptor (NLR) Others
    C12-iE-DAP (Lauroyl-γ-D-glutamyl-meso-diaminopimelic acid) is a biological active peptide. (a lauroyl (C12) group to the glutamic residue of iE-DAP , NOD1 agonist)
    C12-iE-DAP
  • HY-W037451

    Amino Acid Derivatives Others
    Methyl L-leucinate, methyl ester of L-leucine, is an alpha-amino acid ester. Methyl L-leucinate is a derivative of methyl ester and L-leucine, a class of compounds containing both amino and carboxyl groups in the molecule .
    Methyl L-leucinate
  • HY-117141

    AGABA

    Amino Acid Derivatives Others
    N-Arachidonoyl-3-hydroxy-γ-aminobutyric acid is an arachidonoyl amino acid .
    N-Arachidonoyl-3-hydroxy-γ-aminobutyric acid
  • HY-34611

    N-Boc-L-2,4-diaminobutyric acid; Boc-Dab-OH

    Drug Derivative Neurological Disease Cancer
    Boc-L-2,4-Diaminobutyric acid is a derivative of L-2,4-Diaminobutyric acid (HY-101414) [1.
    Boc-L-2,4-Diaminobutyric acid

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: